Corporate Overview

img

Alzheimer's Disease Facts and Figures

Alzamend Neuro®, Inc., (“Alzamend®”), a Delaware corporation with its headquarters in Atlanta, Georgia with nexus in California, is a clinical-stage, biopharmaceutical company. At Alzamend, we are committed to “Making Alzheimer’s Just a Memory™.” Our mission is to rapidly develop and market safe and effective treatments. We are driven by the belief that strong support of research is the foundation for true innovation and uniquely position us to understand and effectively address the unmet needs of the patients we serve. Alzamend strives to provide hope through the commercialization of existing patented intellectual properties and know-how while simultaneously funding future treatments for other neurodegenerative diseases and psychiatric disorders, through advanced research and development.

Our current pipeline consists of two novel therapeutic drug candidates, AL001 – a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 – a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.

Our primary target, Alzheimer’s disease, was among the most-feared diseases (second only to cancer) among Americans, according to a 2011 survey by the Harvard School of Public Health. Alzheimer’s is also the sixth leading cause of death in the United States according to a 2021 report from the Alzheimer’s Association, a nonprofit that funds research. Existing Alzheimer’s treatments only temporarily relieve symptoms but do not slow or halt the underlying worsening of the disease, which currently affects roughly 6.2 million Americans and that number is expected to grow to 13 million individuals by 2050. Alzheimer’s also impacts more than 11 million Americans who provide an estimated 15.3 billion hours of unpaid care per year, valued at $257 billion, according to data provided by the Alzheimer’s Association. In 2021, the estimated healthcare costs for treating individuals with Alzheimer’s in the United States will be $355 billion, including $239 billion in Medicare and Medicaid payments. These costs could rise to as high as $1.1 trillion per year by 2050 if no permanent treatment or cure for Alzheimer’s is found, the Alzheimer’s Association reported.

Our Leadership

Stephan Jackman

Chief Executive Officer and Director 20+ years multi-industry experience, specialized in Biotech and Pharmaceutical LEARN MORE

Kenneth S. Cragun

Senior Vice President of Finance 30+ Years SEC reporting, CFO of publicly-traded company on Nasdaq, multi-industry experience, including Biotech and Healthcare LEARN MORE

Henry C.W. Nisser

Executive Vice President, General Counsel and Director 20+ years experience, U.S. securities compliance, M&A, equity/debt financings and corporate governance LEARN MORE

David J. Katzoff

Chief Operating Officer 30+ Years multi-industry experience, including Healthcare and Technology LEARN MORE

Lien T. Escalona

Chief Financial Officer 25+ Years multi-industry experience with an emphasis on accounting and finance, system implementation and SEC reporting LEARN MORE

Our Board of Directors

Milton C Ault, III

Founder/Chairman Emeritus of Alzamend Executive Chairman of Ault Global Holdings 27+ years Financial Industry experience, seasoned Wall Street CEO & activist investor LEARN MORE

Stephan Jackman

Chief Executive Officer and Director 20+ years multi-industry experience, specialized in Biotech and Pharmaceutical LEARN MORE

William B. Horne

Chairman of Alzamend, Chief Executive Officer of Ault Global Holdings 25+ years Financial Industry experience, prior “Big 4” auditor and healthcare executive LEARN MORE

Henry C.W. Nisser

Executive Vice President, General Counsel and Director 20+ years experience, U.S. securities compliance, M&A, equity/debt financings and corporate governance LEARN MORE

Jeffrey Oram

Principal at Godby Realtors 25+ years multi-industry experience, Investments, Real Estate and Technology LEARN MORE

Mark Gustafson C.P.A.

Chief Financial Officer of PharmaKure Limited 30+ years multi-industry experience as an active CPA, specialized in Biotech, Energy and Technology LEARN MORE

Lynne Fahey McGrath, M.P.H., Ph.D.

Regulatory Affairs and Product Development Consultant 30+ years experience, Biotech and Pharmaceuticals MPH/PHD, Public Health from UMDNJ – Robert Wood Johnson Medical School LEARN MORE

Andrew H. Woo M.D., Ph.D.

Practicing physician at Santa Monica Neurological Consultants, Assistant Clinical Professor of Neurology at the David Geffen School of Medicine at UCLA and Cedars-Sinai Medical Center 20+ years experience in Neurology LEARN MORE

Our Scientific Advisory Board

Eric M. McDade, DO

Associate Director of the DIAN Trials Unit and Clinical Trials Leadership at Washington University School of Medicine Associate Professor of Neurology, Washington University School of Medicine 157+ Peer-Reviewed Journal Publications LEARN MORE

Thomas M. Wisniewski, MD

Director of NYU Langone’s Pearl I. Barlow Center for Memory Evaluation and Treatment 300+ Peer-Reviewed Medical Journal Publications (19 U.S. Patents Issued) Leads a Research Laboratory Continuously Funded by the National Institutes of Health for 20+ Years LEARN MORE

Terri Hunter, Ph.D.

20+ years Experience, Research and Technology Transfer and Partnerships Ph.D. in Medical Sciences from the University of South Florida College of Medicine LEARN MORE